Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/38467
Full metadata record
DC FieldValueLanguage
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorCARVALHO, Joao Paulo Mancusi de
dc.contributor.authorSALIM, Rafael C.
dc.contributor.authorCARVALHO, Filomena Marino
dc.contributor.authorGENTA, Maria Luiza Nogueira Dias
dc.contributor.authorBARACAT, Edmund Chada
dc.contributor.authorCARVALHO, Jesus Paula
dc.date.accessioned2020-12-16T14:54:54Z-
dc.date.available2020-12-16T14:54:54Z-
dc.date.issued2020
dc.identifier.citationJOURNAL OF CLINICAL PATHOLOGY, v.73, n.11, p.748-753, 2020
dc.identifier.issn0021-9746
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/38467-
dc.description.abstractAims L1 cell adhesion molecule (L1CAM) has been shown to be correlated with tumour progression, attributed to its possible association with epithelial-mesenchymal transition (EMT), characterised by the expression of vimentin and loss of e-cadherin. Herein, we investigate the associations between L1CAM and clinicopathological parameters, as well as the expression of vimentin and e-cadherin, in carcinomas restricted to the cervix. Methods The study was retrospective observational and included 45 squamous cell carcinomas (63.4%) and 26 adenocarcinomas (36.6%) submitted to primary surgical treatment. Patient age, FIGO (International Federation of Gynecology and Obstetrics) stage, tumour size and follow-up were obtained from the medical records. All the slides were revised to evaluate histological differentiation, lymphovascular space invasion, depth of infiltration, disease-free cervical wall thickness, pattern of invasion front, Silva pattern (for adenocarcinomas) and the percentage of tumour-infiltrating lymphocytes. Tissue microarrays were constructed for immunohistochemical staining for L1CAM, e-cadherin and vimentin. Results Adenocarcinomas were associated with lower disease-free and overall survival. L1CAM and vimentin expressions were more frequent among adenocarcinomas, although loss of e-cadherin expression was more common among squamous carcinomas. L1CAM expression was associated with larger tumours, vimentin expression and lower disease-free survival. No association was observed between the expression of either L1CAM or vimentin and loss of e-cadherin. High levels of tumour-infiltrating lymphocytes were more frequent in squamous cell carcinoma, high-grade tumours, destructive pattern at front of invasion and loss of e-cadherin expression. Conclusions Our results confirm the prognostic role of L1CAM in cervical carcinomas, but suggest a role for mechanisms other than EMT.eng
dc.language.isoeng
dc.publisherBMJ PUBLISHING GROUPeng
dc.relation.ispartofJournal of Clinical Pathology
dc.rightsrestrictedAccesseng
dc.subjectcervix uterieng
dc.subjectuterine cervical neoplasmseng
dc.subjectimmunohistochemistryeng
dc.subjectpathologyeng
dc.subjectmoleculareng
dc.subjectpathologyeng
dc.subjectsurgicaleng
dc.subject.othere-cadherineng
dc.subject.otherup-regulationeng
dc.subject.othercatenineng
dc.subject.otherprogressioneng
dc.subject.othervimentineng
dc.titleL1 cell adhesion molecule (L1CAM) in stage IB cervical cancer: distinct expression in squamous cell carcinomas and adenocarcinomaseng
dc.typearticleeng
dc.rights.holderCopyright BMJ PUBLISHING GROUPeng
dc.identifier.doi10.1136/jclinpath-2020-206500
dc.identifier.pmid32366597
dc.subject.wosPathologyeng
dc.type.categoryoriginal articleeng
dc.type.versionpublishedVersioneng
hcfmusp.description.beginpage748
hcfmusp.description.endpage753
hcfmusp.description.issue11
hcfmusp.description.volume73
hcfmusp.origemWOS
hcfmusp.origem.idWOS:000583998600012
hcfmusp.origem.id2-s2.0-85094152056
hcfmusp.publisher.cityLONDONeng
hcfmusp.publisher.countryENGLANDeng
hcfmusp.relation.referenceBanister CE, 2017, ONCOTARGET, V8, P13375, DOI 10.18632/oncotarget.14533eng
hcfmusp.relation.referenceBhatla N, 2019, INT J GYNECOL OBSTET, V145, P129, DOI 10.1002/ijgo.12749eng
hcfmusp.relation.referenceBurk RD, 2017, NATURE, V543, P378, DOI 10.1038/nature21386eng
hcfmusp.relation.referenceChen JL, 2018, EXP THER MED, V15, P2792, DOI 10.3892/etm.2018.5747eng
hcfmusp.relation.referenceChen T, 2017, J CELL PHYSIOL, V232, P3261, DOI 10.1002/jcp.25797eng
hcfmusp.relation.referenceCheng Y, 2012, HUM PATHOL, V43, P1213, DOI 10.1016/j.humpath.2011.08.025eng
hcfmusp.relation.referenceDe Vivar AD, 2013, INT J GYNECOL PATHOL, V32, P592, DOI 10.1097/PGP.0b013e31829952c6eng
hcfmusp.relation.referenceEstimativa, 2018, INC CANC BRASeng
hcfmusp.relation.referenceGLOBOCAN, 2018, INC MORT PREV CANC Seng
hcfmusp.relation.referenceGrage-Griebenow E, 2014, MOL ONCOL, V8, P982, DOI 10.1016/j.molonc.2014.03.001eng
hcfmusp.relation.referenceHuszar M, 2010, J PATHOL, V220, P551, DOI 10.1002/path.2673eng
hcfmusp.relation.referenceIchikawa T, 2019, BRIT J CANCER, V121, P1058, DOI 10.1038/s41416-019-0646-8eng
hcfmusp.relation.referenceJiang J, 2019, ONCOL LETT, V17, P5729, DOI 10.3892/ol.2019.10266eng
hcfmusp.relation.referenceKiefel H, 2012, CELL ADHES MIGR, V6, P374, DOI 10.4161/cam.20832eng
hcfmusp.relation.referenceKlat J, 2019, ANTICANCER RES, V39, P421, DOI 10.21873/anticanres.13128eng
hcfmusp.relation.referenceKurman RJ CM, 2014, WHO CLASSIFICATION Teng
hcfmusp.relation.referenceLiu LK, 2010, MODERN PATHOL, V23, P213, DOI 10.1038/modpathol.2009.160eng
hcfmusp.relation.referenceLu W, 2019, DEV CELL, V49, P361, DOI 10.1016/j.devcel.2019.04.010eng
hcfmusp.relation.referencePeng JF, 2016, FUTURE ONCOL, V12, P715, DOI 10.2217/fon.15.332eng
hcfmusp.relation.referenceSalgado R, 2015, ANN ONCOL, V26, P259, DOI 10.1093/annonc/mdu450eng
hcfmusp.relation.referenceSchrevel M, 2017, ONCOTARGET, V8, P87568, DOI 10.18632/oncotarget.20976eng
hcfmusp.relation.referenceSedlis A, 1999, GYNECOL ONCOL, V73, P177, DOI 10.1006/gyno.1999.5387eng
hcfmusp.relation.referenceShtutman M, 2006, CANCER RES, V66, P11370, DOI 10.1158/0008-5472.CAN-06-2106eng
hcfmusp.relation.referenceStewart CJR, 2011, HISTOPATHOLOGY, V58, P720, DOI 10.1111/j.1365-2559.2011.03787.xeng
hcfmusp.relation.referenceStolnicu S, 2018, AM J SURG PATHOL, V42, P214, DOI 10.1097/PAS.0000000000000986eng
hcfmusp.relation.referenceTampakis A, 2020, ACTA ONCOL, V59, P55, DOI 10.1080/0284186X.2019.1667022eng
hcfmusp.relation.referenceTischler V, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-127eng
hcfmusp.relation.referencevan der Maten M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20174180eng
hcfmusp.relation.referenceVersluis MAC, 2018, VIRCHOWS ARCH, V473, P591, DOI 10.1007/s00428-018-2444-8eng
dc.description.indexMEDLINEeng
dc.identifier.eissn1472-4146
hcfmusp.citation.scopus2-
hcfmusp.scopus.lastupdate2022-07-07-
Appears in Collections:

Artigos e Materiais de Revistas Científicas - FM/MOG
Departamento de Obstetrícia e Ginecologia - FM/MOG

Artigos e Materiais de Revistas Científicas - FM/MPT
Departamento de Patologia - FM/MPT

Artigos e Materiais de Revistas Científicas - HC/ICESP
Instituto do Câncer do Estado de São Paulo - HC/ICESP

Artigos e Materiais de Revistas Científicas - HC/ICHC
Instituto Central - HC/ICHC

Artigos e Materiais de Revistas Científicas - LIM/14
LIM/14 - Laboratório de Investigação em Patologia Hepática

Artigos e Materiais de Revistas Científicas - LIM/58
LIM/58 - Laboratório de Ginecologia Estrutural e Molecular

Artigos e Materiais de Revistas Científicas - ODS/03
ODS/03 - Saúde e bem-estar


Files in This Item:
File Description SizeFormat 
art_CARVALHO_L1_cell_adhesion_molecule_L1CAM_in_stage_IB_2020.PDF.pdf
  Restricted Access
publishedVersion (English)451.58 kBAdobe PDFView/Open Request a copy

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.